201 related articles for article (PubMed ID: 11181899)
1. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.
Yamazaki M; Neway WE; Ohe T; Chen I; Rowe JF; Hochman JH; Chiba M; Lin JH
J Pharmacol Exp Ther; 2001 Mar; 296(3):723-35. PubMed ID: 11181899
[TBL] [Abstract][Full Text] [Related]
2. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.
Takeuchi T; Yoshitomi S; Higuchi T; Ikemoto K; Niwa S; Ebihara T; Katoh M; Yokoi T; Asahi S
Pharm Res; 2006 Jul; 23(7):1460-72. PubMed ID: 16779700
[TBL] [Abstract][Full Text] [Related]
4. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.
Luker GD; Rao VV; Crankshaw CL; Dahlheimer J; Piwnica-Worms D
Biochemistry; 1997 Nov; 36(46):14218-27. PubMed ID: 9369495
[TBL] [Abstract][Full Text] [Related]
5. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport.
Katoh M; Suzuyama N; Takeuchi T; Yoshitomi S; Asahi S; Yokoi T
J Pharm Sci; 2006 Dec; 95(12):2673-83. PubMed ID: 16892207
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
Shaik N; Giri N; Pan G; Elmquist WF
Drug Metab Dispos; 2007 Nov; 35(11):2076-85. PubMed ID: 17709369
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse.
Booth-Genthe CL; Louie SW; Carlini EJ; Li B; Leake BF; Eisenhandler R; Hochman JH; Mei Q; Kim RB; Rushmore TH; Yamazaki M
J Pharmacol Toxicol Methods; 2006; 54(1):78-89. PubMed ID: 16545584
[TBL] [Abstract][Full Text] [Related]
9. Transport of phosphatidylcholine in MDR3-negative epithelial cell lines via drug-induced MDR1 P-glycoprotein.
Abulrob AG; Gumbleton M
Biochem Biophys Res Commun; 1999 Aug; 262(1):121-6. PubMed ID: 10448079
[TBL] [Abstract][Full Text] [Related]
10. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
[TBL] [Abstract][Full Text] [Related]
11. Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug.
Jonker JW; Wagenaar E; van Deemter L; Gottschlich R; Bender HM; Dasenbrock J; Schinkel AH
Br J Pharmacol; 1999 May; 127(1):43-50. PubMed ID: 10369454
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.
Kivistö KT; Zukunft J; Hofmann U; Niemi M; Rekersbrink S; Schneider S; Luippold G; Schwab M; Eichelbaum M; Fromm MF
Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):124-30. PubMed ID: 15322734
[TBL] [Abstract][Full Text] [Related]
13. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
Zhou L; Schmidt K; Nelson FR; Zelesky V; Troutman MD; Feng B
Drug Metab Dispos; 2009 May; 37(5):946-55. PubMed ID: 19225039
[TBL] [Abstract][Full Text] [Related]
14. ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate.
Hashimoto N; Nakamichi N; Uwafuji S; Yoshida K; Sugiura T; Tsuji A; Kato Y
J Control Release; 2013 Jan; 165(1):54-61. PubMed ID: 23089896
[TBL] [Abstract][Full Text] [Related]
15. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier.
Matsuzaki J; Yamamoto C; Miyama T; Takanaga H; Matsuo H; Ishizuka H; Kawahara Y; Kuwano M; Naito M; Tsuruo T; Sawada Y
Biopharm Drug Dispos; 1999 Mar; 20(2):85-90. PubMed ID: 10206323
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
[TBL] [Abstract][Full Text] [Related]
17. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
[TBL] [Abstract][Full Text] [Related]
19. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein.
Adachi Y; Suzuki H; Sugiyama Y
Pharm Res; 2001 Dec; 18(12):1660-8. PubMed ID: 11785684
[TBL] [Abstract][Full Text] [Related]
20. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
